Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus Apatinib in Advanced Non-Squamous NSCLC
NCT04670913Phase 2Unknown
- Start
- Jun 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, Rivoceranib in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC). Status: unknown.
02
Drugs
camrelizumabRivoceranib
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT04670913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04670913.